ReviewCurrent HIV/AIDS reports2012
HIV-specific immune dysregulation and atherosclerosis.
Review in Current HIV/AIDS reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Sex differences in cardiovascular disease and associated factors in people living with HIV: Evidence from All of Us program.HIV medicine · 2026Article
- No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors.The Journal of antimicrobial chemotherapy · 2025Article
- Lipids and Body Mass Index in Antiretroviral-Experienced People With HIV on Doravirine-Based Treatments: A Comparison Between Dual or Triple Regimen Versus Bictegravir-Based Triple Regimen.AIDS research and treatment · 2025Article
- Article
- Predicting cardiovascular risk using a novel risk score in young and middle-age adults with HIV: associations with biomarkers and carotid atherosclerotic plaque.International journal of STD & AIDS · 2022Article
- Macrophage Polarity and Disease Control.International journal of molecular sciences · 2021Review
- The role of multimodality imaging in HIV-related heart disease.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2021Article
- Cardiovascular disease among people living with HIV in Brazil.Tropical medicine & international health : TM & IH · 2020Article
- Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.American heart journal · 2019 · on this mapArticle
- Plasma glycomics predict cardiovascular disease in patients with ART-controlled HIV infections.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy.AIDS (London, England) · 2016Article
- Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort study.BMC infectious diseases · 2016Observational
- CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy.AIDS (London, England) · 2016Observational
- Macrophage polarization in pathology.Cellular and molecular life sciences : CMLS · 2015Review
- Taming HIV-related inflammation with physical activity: a matter of timing.AIDS research and human retroviruses · 2014Article
- 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque.AIDS (London, England) · 2014Article
- Cardiovascular disease and HIV infection.Current HIV/AIDS reports · 2013Review
- Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men.AIDS (London, England) · 2013Article
- HIV stroke risk: evidence and implications.Therapeutic advances in chronic disease · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HIV + patients face a heightened risk of cardiovascular disease (CVD), which cannot be fully explained by traditional risk factors or antiretroviral therapy (ART)-related cardiotoxicity. Increasing evidence suggests a significant contribution of HIV-specific immune dysregulation to atherosclerosis. HIV-specific immune dysregulation may have the following atherogenic effects: 1) activation of endothelial and immune cells; 2) enhancement of the percentage of circulating atherogenic immune cell subsets; and 3) modification of lipid function. Efforts are underway to link immune dysregulation markers with validated CVD endpoints and to identify genetic predispositions for HIV-induced atherogenesis. Moreover, immune suppressants are under evaluation in HIV + patients to attempt modification of immune-mediated CVD risk. Taken together, these studies will enhance understanding of CVD risk stratification and reduction strategies in HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.